Skip to main navigation
Skip to search
Skip to main content
King's College London Home
Home
Profiles
Research units
Research output
Projects
Student theses
Activities
Datasets
Impacts
Prizes
Search by expertise, name or affiliation
Negin Sarafraz-Shekary
Dr
32
Citations
Overview
Fingerprint
Network
Research output
(2)
Similar Profiles
(7)
Research output
2
Article
Research output per year
Research output per year
2 results
Publication Year, Title
(descending)
Publication Year, Title
(ascending)
Title
Type
Search results
2019
p38γ MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits calpain through phosphorylation of calpastatin
Loonat, A. A.
,
Martin, E. D.
,
Sarafraz-Shekary, N.
,
Tilgner, K.
, Hertz, N. T., Levin, R., Shokat, K. M., Burlingame, A. L.,
Arabacilar, P.
, Uddin, S., Thomas, M.,
Marber, M. S.
&
Clark, J. E.
,
31 Dec 2019
,
In:
Faseb Journal.
33
,
12
,
p. 13131-13144
14 p.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
File
Phosphorylation
100%
Protein
40%
Knockout Mouse
40%
Isoform
20%
Wild Type
20%
11
Citations (Scopus)
257
Downloads (Pure)
2015
Clinical efficacy and mechanistic evaluation of aflibercept for proliferative diabetic retinopathy (acronym CLARITY): A multicentre phase IIb randomised active-controlled clinical trial
Sivaprasad, S.,
Prevost, A. T.
, Bainbridge, J., Edwards, R. T., Hopkins, D.,
Kelly, J.
, Luthert, P.,
Murphy, C.
, Ramu, J.,
Sarafraz-Shekary, N.
, Vasconcelos, J.,
White-Alao, B.
& Hykin, P.,
14 Aug 2015
,
In:
BMJ Open.
5
,
9
, e008405.
Research output
:
Contribution to journal
›
Article
›
peer-review
Open Access
File
Proliferative Diabetic Retinopathy
100%
Controlled Clinical Trial
100%
Aflibercept
100%
Cost-Effectiveness Analysis
60%
Therapeutic Procedure
40%
22
Citations (Scopus)
183
Downloads (Pure)